References
- Kristoffersen ES and Lundqvist C. Medication-overuse headache: A review. J Pain Res 2014; 7: 367–378.
- Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., ... & Coggeshall, M. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet, 388(10053), 1545-1602.
- International Classification of Headache Disorders. Cephalalgia, 38(1), 1-211
- Bigal, M. E., Serrano, D., Buse, D., Scher, A., Stewart, W. Bigal, M. E., Serrano, D., Buse, D., Scher, A., Stewart, W. F., & Lipton, R. B. (2008). Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population‐based study. Headache: The Journal of Head and Face Pain, 48(8), 1157-1168.
- Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre—Clinical characteristics and treatment outcomes. Cephalalgia. 2004; 24: 483-490. doi: 10.1111/j.1468-2982.2004.00691.x.
- Von Korff M, Galer BS, Stang P. Chronic use of symptomatic headache medications. Pain. 1995;62(2):179-186.
- Tepper J, Tepper DE. Breaking the cycle of medication overuse headache. Cleveland Clin J Med. 2010; 77(4): 236 -242. doi:10.3949/ccjm.77a.09147.
- Edvinsson, L., & Warfvinge, K. (2017). Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia, 0333102417736900.
- Xie, J. Y., De Felice, M., Kopruszinski, C. M., Eyde, N., LaVigne, J., Remeniuk, B., ... & King, T. (2017). Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. Cephalalgia, 37(8), 780-794.
- Franklin GM. Opioids for chronic noncancer pain. Neuro. 2014; 83(14): 1277-1284. doi:10.1212 /WNL.0000000000000839.
- Supornsilpchai, W., le Grand, S. M., & Srikiatkhachorn, A. (2010). Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia, 30(9), 1101-1109.
- De Felice, M., Ossipov, M. H., Wang, R., Dussor, G., Lai, J., Meng, I. D., ... & Dodick, D. (2010). Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain, 133(8), 2475-2488.
- Kopruszinski, C. M., Xie, J. Y., Eyde, N. M., Remeniuk, B., Walter, S., Stratton, J., ... & Porreca, F. (2017). Prevention of stress-or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia, 37(6), 560-570.
- Starling, A. J., Hoffman-Snyder, C., Halker, R. B., Wellik, K. E., Vargas, B. B., Dodick, D. W., ... & Wingerchuk, D. M. (2011). Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. The neurologist, 17(5), 297-299.
- Kroenke K, Spitzer RL, Williams JB. An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics. 2009; 50(6): 613-621. doi: 10.1176/appi.psy.50.6.613.
- Cohen, S., Kamarck, T., & Mermelstein, R. (1994). Perceived stress scale. Measuring stress: A guide for health and social scientists, 235-283.
- Bigal ME, Marcelo E, Lipton RB. Modifiable risk factors for migraine progression. Headache: J Head Face Pain. 2006; 46(9): 1334-1343. doi: 10.1111/j.1526-4610.2006.00577.x.
- Dodick DW. Diagnosing headache: clinical clues and clinical rules. Adv Stud Med. 2003; 3(2): 87-92.
- Young WB, Siow HC. Should butalbital-containing analgesics be banned? Yes. Curr Pain Headache Rep. 2002: 6(2); 151-155. https://www.ncbi.nlm.nih.gov/pubmed/11872187. Accessed January 8, 2018.
- Loder E, Weizenbaum E, Frishberg B, Silberstein S. Choosing wisely in headache medicine: The american headache society’s list of five things physicians and patients should question. Headache: J Head Face Pain. 2013: 53(10); 1651-1659. doi: 10.1111/head.12233.
- Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003; 106: 81-89. doi: 10.1016/S0304-3959(03)00293-8.
- Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000; 47: 614-624.
- Marics, B., Peitl, B., Varga, A., Pázmándi, K., Bácsi, A., Németh, J., ... & Dux, M. (2017). Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses. Cephalalgia, 37(6), 581-591.
- Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med. 1992; 327: 1109-1114. doi: 10.1056/NEJM199210153271601.
- Griffiths RR, Evans SM, Heishman SJ, et al. Lowdose caffeine physical dependence in humans. J Pharmacol Exp Ther. 1990; 255: 1123-1132. http://jpet.aspetjournals.org.offcampus.lib. washington.edu/content/255/3/1123.long. Accessed January 10, 2018.
- Scher AI, Lipton RB, Stewart WF. Habitual snoring as a risk factor for chronic daily headache. Neurology. 2003; 60: 1366-1368. doi: 10.1212/01.WNL.0000055873.71552.51.
- Modgill, G., Jette, N., Wang, J. L., Becker, W. J., & Patten, S. B. (2012). A population‐based longitudinal community study of major depression and migraine. Headache: The Journal of Head and Face Pain, 52(3), 422-432.
- Santos, I. S., Brunoni, A. R., Goulart, A. C., Griep, R. H., Lotufo, P. A., & Benseñor, I. M. (2014). Negative life events and migraine: a cross-sectional analysis of the Brazilian longitudinal study of adult health (ELSA-Brasil) baseline data. BMC public health, 14(1), 678.
- Krøll, L. S., Hammarlund, C. S., Westergaard, M. L., Nielsen, T., Sloth, L. B., Jensen, R. H., & Gard, G. (2017). Level of physical activity, well-being, stress and self-rated health in persons with migraine and co-existing tension-type headache and neck pain. The journal of headache and pain, 18(1), 46.
- Burstein, R., Noseda, R., & Borsook, D. (2015). Migraine: multiple processes, complex pathophysiology. Journal of Neuroscience, 35(17), 6619-6629.
- Deen M. Low 5-HTIB receptor binding in the migraine brain: A PET study. Cephalalgia. 2017; 0(0): 1-9. doi: 10.1177/0333102417698708.
- Medication overuse treatment strategy trial (MOTS). https://www.motstrial.org/. Accessed January 1, 2017.
- Schoenen, J., Vandersmissen, B., Jeangette, S., Herroelen, L., Vandenheede, M., Gérard, P., & Magis, D. (2013). Migraine prevention with a supraorbital transcutaneous stimulator A randomized controlled trial. Neurology, 80(8), 697-704.
- Schoenen, J. E. (2016). Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology, 86(2), 201-202.
- Tassorelli, C., Grazzi, L., de Tommaso, M., Pierangeli, G., Martelletti, P., Rainero, I., ... & Liebler, E. (2018). Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology, 10-1212.
- Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., Pearlman, S. H., ... & Goadsby, P. J. (2010). Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. The Lancet Neurology, 9(4), 373-380.
- Da Silva, A. N., & Lake III, A. E. (2014). Clinical aspects of medication overuse headaches. Headache: The Journal of Head and Face Pain, 54(1), 211-217.
- Plog, B. A., & Nedergaard, M. (2018). The glymphatic system in central nervous system health and disease: past, present, and future. Annual Review of Pathology: Mechanisms of Disease, 13, 379-394.
- Schain, A., Strassman, A., Melo-Carrillo, A., & Burstein, R. (2017). Cortical spreading depression closes the paravascular space and impairs glymphatic flow: Implications for migraine headache.(S47. 001). Neurology, 88(16 Supplement), S47-001.
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: A clinical practice guideline from the american college of physicians. Ann Int Med. 2016; 165(2): 125-133. doi: 10.7326/M15-2175.
- Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized control trial. JAMA. 2001; 11(14): 1856-1864. doi: 10.1001/jama.285.14.1856.
- Tepper SJ. Nutraceutical and Other Modalities for the Treatment of Headache. Neurology Continuum (Minneap Minn) 2015;21:1018–1031
- Facchinetti F, Sances G, Borella P et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991; 31(5): 298-301. doi: 10.1111/j.1526-4610.1991.hed3105298.x.
- Peres, M. F. P., Zukerman, E., da Cunha Tanuri, F., Moreira, F. R., & Cipolla-Neto, J. (2004). Melatonin, 3 mg, is effective for migraine prevention. Neurology, 63(4), 757-757.
- Lampl C, Haider B, Schweiger C. Long-term efficacy of Boswellia serrata in four patients with chronic cluster headache. Cephalalgia. 2012; 719(22). doi: 10.1186/1129-2377-14-S1-P37.
- Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double blind, multicenter, placebo-controlled study. Cephalalgia. 2005. 2005; 25(11): 1031-41.
- Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988; 2(8604): 189-192
- S-Adenosyl-L-Methionine (SAMe): In depth. National Center for Complementary and Integrative Medicine. https://nccih.nih.gov/health/supplements/SAMe
- Tyrer AE, Levitan RD, Houle S, Wilosn AA, Nobrega JN, Rusjan PM, Meyer JH. Serotonin transporter binding is reduced in seasonal affective disorder following light therapy. Acta Psychiatr Scand. 2016; 134: 410-419. doi: 10.1111/acps.12632.
- Williams C. The fire inside. New Scientist. 2017. http://magazinelib.com/all/new-scientist-june-17-23-2017/.
- Junker Y, Zeissig S, Kim S et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med. 2012; 209(13): 2395-2408. doi: 10.1084/jem.20102660.
- Borkum, J. M. (2016). Migraine triggers and oxidative stress: a narrative review and synthesis. Headache: The Journal of Head and Face Pain, 56(1), 12-35.
- Varkey E, Hagen K, Zwart JA, Linde M. Physical activity and headache: results from the nord-trondelag health study (HUNT). Cephalalgia. 2008; 28(12): 1292-1297. doi: 10.1111/j.1468-2982.2008.01678.x.
- Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011; 31(14): 1428-1438. doi: 10.1177/0333102411419681
- Coughlin AM, Badura AS, Fleischer TD, Guck TP. Multidisciplinary treatment of chronic pain patients: its efficacy in changing patient locus of control. Arch Phys Med Rehabil. 2000; 81(6): 739-740. doi: 10.1053/apmr.2000.5586.
- Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback. 2008; 33: 125-40. doi:10.1007/s10484- 008-9060-3.
Last Reviewed on July 25, 2022